Kyle D Buchanan, MD MedStar Washington Hospital Center

Slides:

Advertisements

Similar presentations

STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.

Advertisements

Three-year clinical and echocardiographic follow-up of aortic stenosis patients implanted with a self-expending bioprosthesis Sabine Bleiziffer German.

ACC 2015 Jae K. Oh, MD On Behalf of the US CoreValve Investigators Remodeling of Self-Expanding Transcatheter Aortic Valve Is Responsible for Regression.

ACC 2015 Michael J Reardon, MD, FACC On Behalf of the CoreValve US Investigators A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic.

6-Month Outcomes Following Transcatheter Aortic Valve Implantation With a Novel Repositionable Self-Expanding Bioprosthesis Ian T. Meredith, MBBS, PhD,

Long-Term Outcomes Using a Self- Expanding Bioprosthesis in Patients With Severe Aortic Stenosis Deemed Extreme Risk for Surgery: Two-Year Results From.

Aortic Stenosis and TAVR TARUN NAGRANI, MD INTERVENTIONAL AND ENDOVASCULAR CARDIOLOGIST, SOMC.

University Heart Center Hamburg

TAVR Pearls Addressing the Shortcomings of the Current TAVR Generation

CV 3: Valvular Heart Disease Lab September 19, 2011.

Cardiovascular disease in pregnancy Cardiovascular disease in pregnancy Dr.Z Allameh MD.

Surgical outcome of native valve infective endocarditis in srinagarind hospital

Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III.

Axel Linke University of Leipzig Heart Center, Leipzig, Germany Sabine Bleiziffer German Heart Center, Munich, Germany Johan Bosmans University Hospital.

Trancatheter Aortic Valve Implantation (TAVI)

TCT 2015 | San Francisco | October 15, 2015 Transcatheter Aortic Valve Replacement for Failed Surgical Bioprostheses Danny Dvir, MD John G. Webb, MD and.

TCT 2015 | San Francisco | October 15, 2015 Transcatheter Aortic Valve Replacement for Failed Surgical Bioprostheses Danny Dvir, MD John G. Webb, MD and.

Martin B. Leon, MD on behalf of the PARTNER Investigators TCT 2010; Washington, DC; September 23, 2010 Transcatheter Aortic Valve Implantation in Inoperable.

Prosthetic heart valves: management of usual and unusual complications January 14 th, h-15h30.

Transcatheter Cardiovascular Therapeutics 2008 (October 12-17, 2008 · Washington, DC) First-in-Human Report: Initial Experience with a Stentless and Retrievable.

Causes of Heart Valve Dysfunction Congenital defects (bicuspid aortic valve) Infections (rheumatic fever and bacterial endocarditis Coronary artery disease.

Incidence and Outcomes of Valve Hemodynamic Deterioration in Transcatheter Aortic Valve Replacement in U.S. Clinical Practice: A Report from the Society.

EXPANDING INDICATIONS OF TRANSCATHETER HEART VALVE INTERVENTIONS. JACC CARDIOVASCULAR INTERVENTION. DR.RAJAT GANDHI.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: A Bicuspid Aortic Valve Imaging Classification for.

Twelve Months and Beyond: Long-Term Results of the Direct Flow Medical Repositionable and Retrievable Pericardial Valve for Percutaneous Aortic Valve Replacement.

Primary Mitral Regurgitation Degenerative Mitral Valve Disease

© free-ppt-templates.com 2017 AHA/ACC Focused Update of Valvular Heart Disease Guideline of 2014 DR. OMAR SHAHID TR CARDIOLOGY SZH.

Longest Follow-up After Implantation of a Self-Expanding Repositionable Transcatheter Aortic Valve: Final Follow-up of the Evolut R CE Study Stephen Brecker,

VSD post TAVR: Mechanisms, Presentation and Management

Original slides courtesy of Dr. Alex Morss

Outcomes in the CoreValve US High-Risk Pivotal Trial in Patients with a Society of Thoracic Surgeons Predicted Risk of Mortality Less than or Equal to.

Structural Heart Live Cases

Extending the Boundaries of TAVR: Future Directions

Gates Vascular Institute

Cardiothoracic Surgery

Raj R. Makkar, MD On behalf of The PARTNER Trial Investigators

Direct Flow Medical Experience with a Conformable, Repositionable, Retrievable, Percutaneous Aortic Valve Reginald Low MD University of California,Davis.

Updates From NOTION: The First All-Comer TAVR Trial

TAVR-Endocarditis Tarek Chami, MD

Transcatheter or Surgical Aortic Valve Replacement in Intermediate Risk Patients with Aortic Stenosis Description: The goal of the trial was to assess.

MedStar Washington Hospital Center Cardiac Catheterization Conference

30-Day Safety and Echocardiographic Outcomes Following Transcatheter Aortic Valve Replacement with the Self-Expanding Repositionable Evolut PRO System.

First Report of Three-Year Outcomes With the Repositionable and Fully Retrievable Lotus™ Aortic Valve Replacement System: Results From the REPRISE I.

Early Outcomes with the Evolut R Repositionable Self-Expanding Transcatheter Aortic Valve in the United States Mathew Williams, MD, For the Evolut R US.

Early Recovery of Left Ventricular Systolic Function After CoreValve Transcatheter Aortic Valve Replacement Harold L. Dauerman, MD; Michael J. Reardon,

TAVI „Catch me if you can!“

Longevity of transcatheter and surgical bioprosthetic aortic valves in patients with severe aortic stenosis and lower surgical risk Lars Sondergaard,

CoreValve Continued Access Study Shows Continued Improvement in 1-Year Outcomes With Self-Expanding Transcatheter Aortic Valve Replacement Steven J. Yakubov,

On Behalf of RESOLVE and SAVORY Investigators

Annual Outcomes With Transcatheter Valve Therapy

One Year Outcomes in Real World Patients Treated with Transcatheter Aortic Valve Implantation The ADVANCE Study Axel Linke University of Leipzig Heart.

Managing and Correcting a "Frozen" Leaflet after TAVR

Timing of Intervention in Mitral Stenosis

University Heart Center Hamburg

S.G. Worthley, MB, BS, PhD., S. Redwood, MD, PhD.,

Balloon-Expandable Transcatheter Valve System : OUS Data

TRANSCATHETER MITRAL VALVE IMPLANTATION FOR SEVERE MITRAL REGURGITATION: THE TENDYNE GLOBAL FEASIBILITY TRIAL 1 YEAR OUTCOMES David WM Muller, MBBS,

Annual Outcomes With Transcatheter Valve Therapy

Late Follow-Up from the PARTNER Aortic Valve-in-Valve Registry

Cardiovacular Research Technologies

Samir R. Kapadia, MD On behalf of The PARTNER Trial Investigators

An example adjunctive CT imaging in the management of aortic valve replacement dysfunction. An example adjunctive CT imaging in the management of aortic.

Dehiscence of aortic valve commissure complicated by aortic regurgitation Toshihiro Fukui, MD, Tomoki Shimokawa, MD, Ken-u Fumimoto, MD, Susumu Mananbe,

Five-Year Outcomes after Randomization to Transcatheter or Surgical Aortic Valve Replacement: Final Results of The PARTNER 1 Trial Michael J. Mack, MD.

Structural Heart Live Cases

Slides courtesy of Dr. Randall Harada

Fernanda M. Mangione et al. JIMG 2017;10:82-85

Transesophageal echocardiographic scoring for transcatheter aortic valve implantation: Impact of aortic cusp calcification on postoperative aortic regurgitation

Three mechanisms of early failure of transcatheter aortic valves: Valve thrombosis, cusp rupture, and accelerated calcification Matthew R. Summers, MD,

Structural Heart Live Cases

Presentation transcript:

Kyle D Buchanan, MD MedStar Washington Hospital Center Bioprosthetic Leaflet Thrombosis of Valve-in-Valve Self-Expanding Transcatheter Device Kyle D Buchanan, MD MedStar Washington Hospital Center

Kyle D Buchanan, MD I have no relevant financial relationships

Learning objectives Management of subacute paravalvular bioprosthetic aortic regurgitation. Imaging techniques for the diagnosis of bioprosthetic leaflet thrombosis. Treatment and outcomes of bioprosthetic leaflet thrombosis.

Clinical Presentation 87 year-old female with severe aortic stenosis and symptoms of NYHA Class III dyspnea. Successful implantation of 29 mm Evolut R CoreValve via the transfemoral approach. TAVR procedure complicated by development of heart block requiring permanent pacemaker placement. Discharge echocardiogram demonstrated mild to moderate transvalvular aortic regurgitation.

Clinical Presentation Readmitted with recurrent NYHA Class III heart failure symptoms one month following TAVR. Echocardiogram demonstrated moderate posterior paravalvular regurgitation.

Clinical Presentation Readmitted with recurrent NYHA Class III heart failure symptoms one month following TAVR. Echocardiogram demonstrated moderate posterior paravalvular regurgitation.

Clinical Presentation Successful abolition of aortic regurgitation with placement of second 29 mm Evolut R CoreValve.

Clinical Presentation 6-month follow-up clinic visit. Functionally limited by lumbar compression fractures but ambulates with walker. Denies significant dyspnea, chest pain, dizziness, syncope, PND, orthopnea, and lower extremity swelling. Maintains regular follow-up with general Cardiologist. Compliant with Apixaban treatment for atrial fibrillation

Clinical Presentation 6-month follow-up echo demonstrated normal functioning bioprosthetic valve with no regurgitation.

Imaging studies “Right” and “left” cusp leaflet thickening. Normal non-coronary cusp. “LCC” “RCC” “RCC” “NCC”

Imaging studies “RCC” “NCC” “LCC”

Imaging studies

Imaging studies

Follow-Up Apixaban discontinued, transitioned to Warfarin therapy (goal INR 2-3). Repeat CT scan to be completed following 3 months of Warfarin treatment. Repeat imaging will be available for presentation in February at CRT 2017.

Take Home Messages Subclinical leaflet thrombosis may occur during Factor Xa inhibitor therapy. Valve-in-valve prosthesis hemodynamics may portend higher risk of leaflet thrombosis. TTE is not sufficient to diagnose subclinical leaflet thrombosis, CT or TEE is required. Treatment with Warfarin, results are pending.